PCTR2

PCTR2 (Protectin Conjugate in Tissue Regeneration 2) is a specialized pro-resolving mediator (SPM) and a member of the protectin family of bioactive lipids. It is a sulfidoconjugated derivative of docosahexaenoic acid (DHA), specifically identified as 16R-glutathionyl, 17S-hydroxy-4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid. PCTR2 plays a critical role in the resolution phase of inflammation by promoting tissue repair, stimulating the clearance of apoptotic cells and cellular debris (efferocytosis), and modulating immune cell functions. In preclinical research, PCTR2 has demonstrated significant potential in preventing cancer cachexia, a syndrome characterized by progressive weight loss and muscle wasting, by counter-regulating pro-inflammatory cytokines and enhancing resolution pathways. The molecule was identified and characterized by researchers at Brigham and Women's Hospital and Harvard Medical School, particularly within the laboratory of Charles N. Serhan.

Other names

protectin conjugate in tissue regeneration 216R-glutathionyl, 17S-hydroxy-4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid